Irbesartan Ratiopharm

Irbesartan, the active ingredient in Irbesartan Ratiopharm, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It belongs to the antihypertensive therapeutic class and is used to lower elevated blood pressure and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to manage conditions related to high blood pressure and renal impairment.

Hypertension: reduces systolic and diastolic blood pressure, improving overall cardiovascular risk. Diabetic nephropathy: slows progression of kidney damage in type 2 diabetes and reduces proteinuria. Cardiovascular risk reduction: lowers the incidence of stroke and myocardial events in patients with hypertension.

Irbesartan may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness - Headache - Fatigue - Upper respiratory tract infection - Nausea - Diarrhea

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Hyperkalaemia (elevated serum potassium) - Acute renal failure or worsening renal function - Hepatic injury (elevated liver enzymes, jaundice)

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure patient safety.

Monitor blood pressure: check regularly to assess therapeutic response. Assess renal function: evaluate serum creatinine and eGFR before and during treatment. Check serum potassium: monitor for hyperkalaemia, especially with concomitant potassium‑sparing agents. Use caution in severe hepatic impairment: dose adjustment may be required. Avoid use in pregnancy: drug may harm the fetus. Store at room temperature: keep in original packaging, protect from moisture and light.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - ACE inhibitors: combined use increases risk of angioedema and hyperkalaemia. - Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium. - Aliskiren (in diabetes): co‑administration can lead to renal impairment and hyperkalaemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and affect renal function. - Thiazide diuretics: additive blood‑pressure lowering effect may require dose adjustment.